These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36079026)

  • 1. Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain).
    Ruiz-Villaverde R; Rodriguez Fernandez-Freire L; Font-Ugalde P; Galan-Gutierrez M
    J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36079026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brodalumab: Efficacy, safety, and survival in mid-term (52 weeks) on real clinical practice in Andalucia, Spain.
    Galan-Gutierrez M; Font-Ugalde P; Padilla L; Hernandez-Montoya C; Godoy D; Armario-Hita JC; Ruiz-Villaverde R
    Int J Dermatol; 2023 May; 62(5):700-706. PubMed ID: 36495585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines.
    Ruiz-Villaverde R; Rodriguez-Fernandez-Freire L; Pérez-Gil A; Font-Ugalde P; Galán-Gutiérrez M
    Life (Basel); 2022 Nov; 12(11):. PubMed ID: 36431015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guselkumab: Mid-term effectiveness, drug survival, and safety in real clinical practice.
    Ruiz-Villaverde R; Rodriguez-Fernandez-Freire L; Armario-Hita JC; Pérez-Gil A; Galán-Gutiérrez M
    Dermatol Ther; 2021 Mar; 34(2):e14798. PubMed ID: 33484067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1).
    Igarashi A; Nakagawa H; Morita A; Okubo Y; Sano S; Imafuku S; Tada Y; Honma M; Mendelsohn AM; Kawamura M; Ohtsuki M
    J Dermatol; 2021 Jun; 48(6):853-863. PubMed ID: 33630387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study.
    Megna M; Tommasino N; Potestio L; Battista T; Ruggiero A; Noto M; Fabbrocini G; Genco L
    J Dermatolog Treat; 2022 Sep; 33(6):2813-2820. PubMed ID: 35603992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study.
    Caldarola G; Galluzzo M; Bernardini N; Calabrese L; Grimaldi M; Moretta G; Pagnanelli G; Shumak RG; Talamonti M; Tofani L; Pallotta S; Peris K; Potenza C; De Simone C; Campione E
    Dermatol Ther; 2022 Jun; 35(6):e15488. PubMed ID: 35384168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Tildrakizumab Across Different Body Weights in Moderate-to-Severe Psoriasis Over 5 Years: Pooled Analyses from the reSURFACE Pivotal Studies.
    Thaçi D; Gerdes S; Du Jardin KG; Perrot JL; Puig L
    Dermatol Ther (Heidelb); 2022 Oct; 12(10):2325-2341. PubMed ID: 36098877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis).
    Narcisi A; Valenti M; Gargiulo L; Ibba L; Amoruso F; Argenziano G; Bardazzi F; Burlando M; Carrera CG; Damiani G; Dapavo P; Dini V; Franchi C; Girolomoni G; Guarneri C; Loconsole F; Sampogna F; Travaglini M; Malagoli P; Costanzo A
    J Eur Acad Dermatol Venereol; 2023 Jan; 37(1):93-103. PubMed ID: 36156312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
    Reich K; Papp KA; Blauvelt A; Tyring SK; Sinclair R; Thaçi D; Nograles K; Mehta A; Cichanowitz N; Li Q; Liu K; La Rosa C; Green S; Kimball AB
    Lancet; 2017 Jul; 390(10091):276-288. PubMed ID: 28596043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate-to-severe chronic plaque psoriasis.
    Poulin Y; Ramon M; Rosoph L; Weisman J; Mendelsohn AM; Parno J; Rozzo SJ; Lee P
    J Eur Acad Dermatol Venereol; 2020 Jul; 34(7):1500-1509. PubMed ID: 31919889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice.
    Ruggiero A; Fabbrocini G; Cinelli E; Ocampo Garza SS; Camela E; Megna M
    Clin Exp Dermatol; 2022 Mar; 47(3):561-567. PubMed ID: 34642965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
    Papp K; Thaçi D; Reich K; Riedl E; Langley RG; Krueger JG; Gottlieb AB; Nakagawa H; Bowman EP; Mehta A; Li Q; Zhou Y; Shames R
    Br J Dermatol; 2015 Oct; 173(4):930-9. PubMed ID: 26042589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.
    Reich K; Warren RB; Iversen L; Puig L; Pau-Charles I; Igarashi A; Ohtsuki M; Falqués M; Harmut M; Rozzo S; Lebwohl MG; Cantrell W; Blauvelt A; Thaçi D
    Br J Dermatol; 2020 Mar; 182(3):605-617. PubMed ID: 31218661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting.
    Burlando M; Castelli R; Cozzani E; Parodi A
    Drugs Context; 2021; 10():. PubMed ID: 34104197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1).
    Imafuku S; Nakagawa H; Igarashi A; Morita A; Okubo Y; Sano S; Tada Y; Nemoto O; Rozzo SJ; Kawamura M; Ohtsuki M
    J Dermatol; 2021 Jun; 48(6):844-852. PubMed ID: 33523513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psoriasis patients' characteristics associated with high PASI response to tildrakizumab: an international dual center study.
    Burlando M; Maul JT; Salvi I; Simic D; Cozzani E; Ak M; Birkenmaier I; Parodi A
    Eur Rev Med Pharmacol Sci; 2022 Sep; 26(18):6772-6776. PubMed ID: 36196725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2).
    Thaci D; Piaserico S; Warren RB; Gupta AK; Cantrell W; Draelos Z; Foley P; Igarashi A; Langley RG; Asahina A; Young M; Falqués M; Pau-Charles I; Mendelsohn AM; Rozzo SJ; Reich K
    Br J Dermatol; 2021 Aug; 185(2):323-334. PubMed ID: 33544883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
    Blauvelt A; Leonardi CL; Gooderham M; Papp KA; Philipp S; Wu JJ; Igarashi A; Flack M; Geng Z; Wu T; Camez A; Williams D; Langley RG
    JAMA Dermatol; 2020 Jun; 156(6):649-658. PubMed ID: 32267471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
    Crowley JJ; Langley RG; Gordon KB; Pinter A; Ferris LK; Rubant S; Photowala H; Xue Z; Wu T; Zhan T; Beeck S; Shah M; Warren RB
    Dermatol Ther (Heidelb); 2022 Feb; 12(2):561-575. PubMed ID: 35050485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.